| Literature DB >> 11295430 |
J M Jeong1, Y J Kim, Y S Lee, J I Ko, M Son, D S Lee, J K Chung, J H Park, M C Lee.
Abstract
Radiolabeled lipiodol has been used for targeting liver cancer. We developed a lipiodol solution of (188)Re-TDD (2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol) and investigated its feasibility for the treatment of liver cancer. The lipiodol solution of (188)Re-TDD was well-retained in the lipiodol phase in vitro. After injection through the tail veins of mice, high lung-uptake was investigated which is evidence of embolizing activity. We also found high accumulation in hepatoma after injection through the hepatic arteries of hepatoma-bearing rats. In conclusion, the lipiodol solution of (188)Re-TDD is a promising agent for liver cancer therapy.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11295430 DOI： 10.1016/s0969-8051(00)00208-0
Source DB: PubMed Journal: Nucl Med Biol ISSN： 0969-8051 Impact factor: 2.408